| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Calithera Biosciences Inc (NASDAQ: CALA)
CALA Technical Analysis
5
| As on 9th Jun 2023 CALA STOCK Price closed @ 0.36 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.69 & Strong Sell for SHORT-TERM with Stoploss of 0.54 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CALASTOCK Price
| Open | 0.35 | Change | Price | % |
| High | 0.36 | 1 Day | 0.01 | 2.86 |
| Low | 0.35 | 1 Week | 0.00 | 0.00 |
| Close | 0.36 | 1 Month | 0.32 | 800.00 |
| Volume | 4102 | 1 Year | -0.32 | -47.06 |
| 52 Week High 4.88 | 52 Week Low 0.02 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CALA Daily Charts |
CALA Intraday Charts |
Whats New @ Bazaartrend |
CALA Free Analysis |
|
|
CALA Important Levels Intraday
| RESISTANCE | 0.38 |
| RESISTANCE | 0.37 |
| RESISTANCE | 0.37 |
| RESISTANCE | 0.37 |
| SUPPORT | 0.35 |
| SUPPORT | 0.35 |
| SUPPORT | 0.35 |
| SUPPORT | 0.34 |
CALA Forecast May 2024
| 4th UP Forecast | 1.03 |
| 3rd UP Forecast | 0.82 |
| 2nd UP Forecast | 0.68 |
| 1st UP Forecast | 0.55 |
| 1st DOWN Forecast | 0.17 |
| 2nd DOWN Forecast | 0.04 |
| 3rd DOWN Forecast | -0.1 |
| 4th DOWN Forecast | -0.31 |
CALA Weekly Forecast
| 4th UP Forecast | 0.61 |
| 3rd UP Forecast | 0.53 |
| 2nd UP Forecast | 0.48 |
| 1st UP Forecast | 0.43 |
| 1st DOWN Forecast | 0.29 |
| 2nd DOWN Forecast | 0.24 |
| 3rd DOWN Forecast | 0.19 |
| 4th DOWN Forecast | 0.11 |
CALA Forecast2024
| 4th UP Forecast | 10.13 |
| 3rd UP Forecast | 7 |
| 2nd UP Forecast | 5.06 |
| 1st UP Forecast | 3.12 |
| 1st DOWN Forecast | -2.4 |
| 2nd DOWN Forecast | -4.34 |
| 3rd DOWN Forecast | -6.28 |
| 4th DOWN Forecast | -9.41 |
Calithera Biosciences Inc ( NASDAQ USA Symbol : CALA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CALA Business Profile
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor that is in Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and CB-708, an orally administered small molecule inhibitor of CD73, as well as CB-668, an inhibitor of the enzyme IL4I1. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. The company also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, it has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. Address: 343 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service